Is flecainide dangerous in long QT-3 patients?

Roy Beinart, Athanasios Michailidis, Osnat T. Gurevitz, Michael Glikson*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Mutations of the cardiac sodium channel gene, SCN5A, are present in both long-QT and Brugada syndromes. Flecainide is used as a provocative test to unmask the electrocardiogram (ECG) phenotype of the Brugada syndrome, as well as long-term treatment for long QT-3 syndrome, since it shortens the QT interval. We report a case where oral flecainide induced syncope with a Brugada ECG pattern in a patient with known long QT-3 syndrome.

Original languageEnglish
Pages (from-to)143-145
Number of pages3
JournalPACE - Pacing and Clinical Electrophysiology
Issue number1
StatePublished - Jan 2009


  • Defibrillation-ICD
  • Long QT


Dive into the research topics of 'Is flecainide dangerous in long QT-3 patients?'. Together they form a unique fingerprint.

Cite this